Telo Genomics Corp. (TDSGF)
USD 0.08
(14.29%)
USD 0.08
(14.29%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.64 Million CAD | 0.46% |
| 2022 | -2.65 Million CAD | 26.23% |
| 2021 | -3.59 Million CAD | -308.24% |
| 2020 | -880.98 Thousand CAD | -438.18% |
| 2019 | 260.5 Thousand CAD | 486.9% |
| 2018 | -67.33 Thousand CAD | 94.39% |
| 2017 | -1.2 Million CAD | -4581.09% |
| 2016 | 26.78 Thousand CAD | 110.41% |
| 2015 | -257.26 Thousand CAD | 49.23% |
| 2014 | -506.69 Thousand CAD | 6.54% |
| 2013 | -542.17 Thousand CAD | -668.29% |
| 2012 | -70.56 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -690.88 Thousand CAD | 45.28% |
| 2024 Q2 | -1.26 Million CAD | 35.09% |
| 2024 Q1 | -1.94 Million CAD | 26.34% |
| 2023 Q1 | -2.07 Million CAD | 21.65% |
| 2023 Q2 | -1.37 Million CAD | 33.93% |
| 2023 Q3 | -680.57 Thousand CAD | 50.45% |
| 2023 FY | -2.64 Million CAD | 0.46% |
| 2023 Q4 | -2.64 Million CAD | -288.01% |
| 2022 Q3 | -3.12 Million CAD | 12.36% |
| 2022 FY | -2.65 Million CAD | 26.23% |
| 2022 Q1 | -3.76 Million CAD | -4.59% |
| 2022 Q2 | -3.56 Million CAD | 5.26% |
| 2022 Q4 | -2.65 Million CAD | 15.05% |
| 2021 FY | -3.59 Million CAD | -308.24% |
| 2021 Q1 | -780.15 Thousand CAD | 11.44% |
| 2021 Q2 | -1.61 Million CAD | -106.43% |
| 2021 Q3 | -1.92 Million CAD | -19.49% |
| 2021 Q4 | -3.59 Million CAD | -86.9% |
| 2020 Q3 | -1.01 Million CAD | 31.54% |
| 2020 FY | -880.98 Thousand CAD | -438.18% |
| 2020 Q2 | -1.47 Million CAD | -443.33% |
| 2020 Q1 | 430.06 Thousand CAD | 65.09% |
| 2020 Q4 | -880.98 Thousand CAD | 12.85% |
| 2019 FY | 260.5 Thousand CAD | 486.9% |
| 2019 Q3 | 155.75 Thousand CAD | 64.74% |
| 2019 Q2 | 94.54 Thousand CAD | 4399.41% |
| 2019 Q4 | 260.5 Thousand CAD | 67.25% |
| 2019 Q1 | -2199.00 CAD | 96.73% |
| 2018 Q1 | -366.66 Thousand CAD | 69.45% |
| 2018 FY | -67.33 Thousand CAD | 94.39% |
| 2018 Q4 | -67.33 Thousand CAD | 89.11% |
| 2018 Q3 | -618.41 Thousand CAD | 56.52% |
| 2018 Q2 | -1.42 Million CAD | -287.86% |
| 2017 Q2 | -3.58 Million CAD | -101.72% |
| 2017 Q4 | -1.2 Million CAD | 52.98% |
| 2017 Q1 | -1.77 Million CAD | -1632.99% |
| 2017 FY | -1.2 Million CAD | -4581.09% |
| 2017 Q3 | -2.55 Million CAD | 28.71% |
| 2016 Q3 | 102.25 Thousand CAD | 132.1% |
| 2016 Q2 | -318.54 Thousand CAD | 49.19% |
| 2016 Q4 | 115.79 Thousand CAD | 13.24% |
| 2016 FY | 26.78 Thousand CAD | 110.41% |
| 2016 Q1 | -626.88 Thousand CAD | -164.68% |
| 2015 Q4 | -236.84 Thousand CAD | 48.53% |
| 2015 Q2 | -459.92 Thousand CAD | 1.04% |
| 2015 Q3 | -460.19 Thousand CAD | -0.06% |
| 2015 FY | -257.26 Thousand CAD | 49.23% |
| 2015 Q1 | -464.77 Thousand CAD | 2.62% |
| 2014 Q3 | -525.61 Thousand CAD | -3.73% |
| 2014 FY | -506.69 Thousand CAD | 6.54% |
| 2014 Q1 | -512.93 Thousand CAD | 1.06% |
| 2014 Q4 | -477.26 Thousand CAD | 9.2% |
| 2014 Q2 | -506.69 Thousand CAD | 1.22% |
| 2013 Q3 | -546.33 Thousand CAD | -0.77% |
| 2013 Q1 | -544.55 Thousand CAD | 2.9% |
| 2013 Q2 | -542.17 Thousand CAD | 0.44% |
| 2013 FY | -542.17 Thousand CAD | -668.29% |
| 2013 Q4 | -518.45 Thousand CAD | 5.1% |
| 2012 Q4 | -560.83 Thousand CAD | 1.49% |
| 2012 FY | -70.56 Thousand CAD | 0.0% |
| 2012 Q3 | -569.29 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | 219.707% |
| Arrayit Corporation | 1.05 Million USD | 350.17% |
| Atlantic International Corp. | 236.49 Thousand USD | 1216.614% |
| Biocept, Inc. | -788 Thousand USD | -235.12% |
| Bioqual, Inc. | -12 Million USD | 78.007% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | 11713.294% |
| DermTech, Inc. | 17.65 Million USD | 114.959% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 99.539% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | 64.203% |
| iMD Companies, Inc. | 1.11 Million USD | 336.644% |
| IDenta Corp. | 524.85 Thousand USD | 603.141% |
| Interpace Biosciences, Inc. | 7.69 Million USD | 134.322% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | -9697.963% |
| InVitro International | -313.14 Thousand USD | -743.307% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | 268.639% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | -370271.248% |
| Medical Imaging Corp. | 3.79 Million USD | 169.66% |
| NovelStem International Corp. | 3.52 Million USD | 174.988% |
| Optigenex Inc. | 8.93 Million USD | 129.558% |
| PharmChem, Inc. | -1.49 Million USD | -76.708% |
| Proteome Sciences plc | 14.57 Million USD | 118.12% |
| Response Genetics, Inc | -13.08 Million USD | 79.82% |
| Rennova Health, Inc. | 14.82 Million USD | 117.807% |
| RushNet, Inc. | 4.8 Million USD | 155.006% |
| ScreenPro Security Inc. | 135.58 Thousand USD | 2047.612% |
| Stella Diagnostics Inc. | 6.19 Million USD | 142.64% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | 247.991% |
| Todos Medical Ltd. | 38.31 Million USD | 106.892% |